These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 29447137)

  • 1. Emerging therapies for neuropathic pain: new molecules or new indications for old treatments?
    Bouhassira D; Attal N
    Pain; 2018 Mar; 159(3):576-582. PubMed ID: 29447137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voltage-gated Na+ channels in neuropathic pain.
    Hargus NJ; Patel MK
    Expert Opin Investig Drugs; 2007 May; 16(5):635-46. PubMed ID: 17461737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective small molecule angiotensin II type 2 receptor antagonists for neuropathic pain: preclinical and clinical studies.
    Smith MT; Anand P; Rice ASC
    Pain; 2016 Feb; 157 Suppl 1():S33-S41. PubMed ID: 26785154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DRG Voltage-Gated Sodium Channel 1.7 Is Upregulated in Paclitaxel-Induced Neuropathy in Rats and in Humans with Neuropathic Pain.
    Li Y; North RY; Rhines LD; Tatsui CE; Rao G; Edwards DD; Cassidy RM; Harrison DS; Johansson CA; Zhang H; Dougherty PM
    J Neurosci; 2018 Jan; 38(5):1124-1136. PubMed ID: 29255002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Old Friends With New Faces: Are Sodium Channel Blockers the Future of Adjunct Pain Medication Management?
    Thomas AM; Atkinson TJ
    J Pain; 2018 Jan; 19(1):1-9. PubMed ID: 28842369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elucidation of pathophysiology and treatment of neuropathic pain.
    Vranken JH
    Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):304-14. PubMed ID: 23033930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological and non-pharmacological treatments for neuropathic pain: Systematic review and French recommendations.
    Moisset X; Bouhassira D; Avez Couturier J; Alchaar H; Conradi S; Delmotte MH; Lanteri-Minet M; Lefaucheur JP; Mick G; Piano V; Pickering G; Piquet E; Regis C; Salvat E; Attal N
    Rev Neurol (Paris); 2020 May; 176(5):325-352. PubMed ID: 32276788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective Na
    Bankar G; Goodchild SJ; Howard S; Nelkenbrecher K; Waldbrook M; Dourado M; Shuart NG; Lin S; Young C; Xie Z; Khakh K; Chang E; Sojo LE; Lindgren A; Chowdhury S; Decker S; Grimwood M; Andrez JC; Dehnhardt CM; Pang J; Chang JH; Safina BS; Sutherlin DP; Johnson JP; Hackos DH; Robinette CL; Cohen CJ
    Cell Rep; 2018 Sep; 24(12):3133-3145. PubMed ID: 30231997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropathic pain: preclinical and early clinical progress with voltage-gated sodium channel blockers.
    Kushnarev M; Pirvulescu IP; Candido KD; Knezevic NN
    Expert Opin Investig Drugs; 2020 Mar; 29(3):259-271. PubMed ID: 32070160
    [No Abstract]   [Full Text] [Related]  

  • 10. Emerging Treatments for Neuropathic Pain.
    Pessoa BL; Escudeiro G; Nascimento OJ
    Curr Pain Headache Rep; 2015 Dec; 19(12):56. PubMed ID: 26530058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a novel series of pyridone amides as Na
    Wang Y; Hu S; Chen Y; Chen M; Zhang D; Liu W; Chen C; Gan Y; Luo M; Ke B
    Bioorg Med Chem Lett; 2024 Mar; 101():129655. PubMed ID: 38350529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel sodium channel antagonists in the treatment of neuropathic pain.
    Rivara M; Zuliani V
    Expert Opin Investig Drugs; 2016; 25(2):215-26. PubMed ID: 26576738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain.
    Smith MT; Muralidharan A
    Expert Opin Ther Targets; 2015 Jan; 19(1):25-35. PubMed ID: 25315162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy and noninvasive neurostimulation for neuropathic pain.
    Spagna A; Attal N
    Presse Med; 2024 Jun; 53(2):104233. PubMed ID: 38636787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future treatment strategies for neuropathic pain.
    Marchand F; Jones NG; McMahon SB
    Handb Exp Pharmacol; 2009; (194):589-615. PubMed ID: 19655119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II type 2-receptor: new clinically validated target in the treatment of neuropathic pain.
    Rice AS; Smith MT
    Clin Pharmacol Ther; 2015 Feb; 97(2):128-30. PubMed ID: 25670516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New investigational drugs for the treatment of neuropathic pain.
    Sałat K; Kowalczyk P; Gryzło B; Jakubowska A; Kulig K
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1093-104. PubMed ID: 24896842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No gain, no pain: NaV1.7 as an analgesic target.
    King GF; Vetter I
    ACS Chem Neurosci; 2014 Sep; 5(9):749-51. PubMed ID: 25111714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and Evaluation of Novel α-Aminoamides Containing an Indole Moiety for the Treatment of Neuropathic Pain.
    Li H; Fan S; Cheng J; Zhang P; Zhong B; Shi W
    Molecules; 2016 Jun; 21(7):. PubMed ID: 27347907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoarthritis-dependent changes in antinociceptive action of Nav1.7 and Nav1.8 sodium channel blockers: An in vivo electrophysiological study in the rat.
    Rahman W; Dickenson AH
    Neuroscience; 2015 Jun; 295():103-16. PubMed ID: 25818052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.